Vor Biopharma Inc. Shareholders' Equity
Vor Biopharma Inc. (VOR) had Shareholders' Equity of -$200.20 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent -$200.20M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$150.42M; Stockholders' Equity Attributable to Parent as first filed -$150.42M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$164.31M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$2.23B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$200.20M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$150.42M 10-Q · filed 2026-08-11 | -$150.42M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$164.31M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$2.23B 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$1.51B 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $66.07M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $96.66M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $72.95M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $98.08M 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $123.03M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $150.72M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $174.78M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $204.45M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $230.22M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $250.61M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $158.73M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $174.97M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $194.45M 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $216.26M 10-K · filed 2024-03-20 | |
| 2021-09-30 | $232.96M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $250.11M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $267.19M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | -$59.06M 10-K · filed 2023-03-23 | |
| 2020-09-30 | -$44.14M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$32.99M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$25.12M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | -$17.43M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |